ASCO GI Highlights

March 2023, Vol 4, No 1 — April 4, 2023
Researchers examined the characteristics, outcomes, and genomic profiles of patients with advanced biliary tract cancer who were treated with durvalumab plus gemcitabine/cisplatin and experienced long-term survival.
Read More

March 2023, Vol 4, No 1 — April 4, 2023
The novel MDM2-p53 antagonist BI 907828 is being investigated as a first-line treatment in patients with advanced biliary tract cancer.
Read More

March 2023, Vol 4, No 1 — April 4, 2023
Long-term outcomes were evaluated in patients with IDH1-mutated biliary tract cancer who were treated with systemic therapy.
Read More

March 2023, Vol 4, No 1 — April 4, 2023
CTX-009 plus paclitaxel showed promising efficacy as second- or third-line treatment in patients with advanced biliary tract cancer.
Read More

March 2023, Vol 4, No 1 — April 4, 2023
Gunagratinib showed promising efficacy as a second-generation FGFR inhibitor and demonstrated potential to treat multiple FGFR pathway abnormalities.
Read More

March 2023, Vol 4, No 1 — April 4, 2023
The SWOG 1815 trial found that treatment with gemcitabine/cisplatin and paclitaxel (GAP) did not result in a significant improvement in survival compared with gemcitabine and cisplatin in patients with advanced biliary tract cancer, though GAP may be beneficial in patients with locally advanced disease and GBC.
Read More

March 2023, Vol 4, No 1 — April 4, 2023
A study of patients with resected biliary tract cancer (BTC) found that postoperative CA 19-9 level, tumor differentiation, lymph node metastases, and residual tumor significantly impact early relapse in patients with curatively resected BTC. Similar risk factors were also found in patients receiving adjuvant S-1.
Read More

March 2023, Vol 4, No 1 — April 4, 2023
Results from a study evaluating the impact of 5-FU metabolic pathway enzyme expression on outcomes of patients with curatively resected biliary tract cancer showed that relapse-free survival was improved in patients with certain enzymes who received adjuvant S-1.
Read More

March 2023, Vol 4, No 1 — April 4, 2023
Researchers assessed whether VEGF blockade plus chemotherapy with gemcitabine/cisplatin can enhance responses to PD-L1 inhibition by promoting an immune-permissive tumor microenvironment in patients with advanced biliary tract cancer.
Read More

March 2023, Vol 4, No 1 — April 4, 2023
The safety and efficacy of second-line nab-paclitaxel combined with the anti-PD-1 antibody sintilimab was studied in patients with advanced biliary tract cancer.
Read More

Page 1 of 4


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: